IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the Barclays 27 th Annual Global ...

XDEMVY (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis.

is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the ...

The mucus comes from the conjunctiva which is the transparent tissue covering the whites of the eye and internal surface of ...

Good morning, and welcome to Tarsus Year End 2024 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to David Nakasone, ...

Q4 2024 Earnings Call Transcript February 25, 2025 Tarsus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Good morning and welcome to Tarsus this year in 2024 financial results conference call. As a reminder, this call is being recorded at this time. I would like to turn the call over to David Nakasone, ...

Treating a stye requires a light-handed approach. We spoke with experts about how to do so at home along with tips and ...

A lot of times, the inflammatory component will get better by treating the ocular surface with lid ... you have watch out for things like rosacea, blepharitis, Demodex and staphylococcal marginal ...